Anti-TROP2 Antibody, clone 2O13 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 21amino acids from the extracellular domain of human TROP2.

Quality Control Testing

Evaluated by Western Blotting in SK-BR-3 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected TROP2 in SK-BR-3 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected TROP2 in HaCaT cell lysate and a 1:1,000 dilution detected TROP2 in human kidney tissue lysate.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected TROP2 in HaCaT cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected TROP2 in human skin tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound TROP2 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Tumor-associated calcium signal transducer 2 (UniProt: P09758; also known as Cell surface glycoprotein Trop-2, Trophoblast antigen 2, Membrane component chromosome 1 surface marker 1, Pancreatic carcinoma marker protein GA733-1) is encoded by the TACSTD2 (also known as GA733-1, M1S1, TROP2) gene (Gene ID: 4070) in human. Trop2 is a single-pass type 1 membrane glycoprotein that is synthesized with a signal peptide (aa 1-26), which is subsequently cleaved off to generate the mature form that contains an extracellular domain (aa 27-274), a transmembrane domain (aa 275-297), and a cytoplasmic domain (aa 298-323). Its expression is observed in placenta and is highly expressed in many cancers where it plays a role in tumor progression. About 85% of all solid cancers display increased expression of Trop2. Its expression is also reported in stem cells in various tissues. TROP2 expression in cancer cells has been correlated with drug resistance. Upregulation of Trop2 is reported to drive the expression and activation of CREB1, Jun, NF- kB, Rb, STAT1, and STAT3 through induction of the cyclin D1 and the ERK pathways. Mutations in TROP2 is known to cause corneal dystrophy of the gelatinous drop-like type (GDLD), an autosomal recessive disorder that is characterized by pathognomonic branching lattice figures in the cornea leading to blindness. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Sayama, Y., et al. (2021). Biochem. Biophys. Rep. 25; 100902; Shvartsur, A., and Bonavida, B. (2015). Genes Cancer. 6(3-4); 84-105).

Clone 2O13 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects TROP2. It targets an epitope within 21 amino acids from the extracellular domain.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.